KALA BIO’s latest 10-Q filing outlines its ongoing transition from disrupted biologics development to an exclusive AI platform license targeting biotech and pharmaceutical companies. After discontinuing the KPI-012 biologic following a failed Phase 2b trial, the company secured worldwide rights to Researgency, an AI infrastructure platform emphasizing data privacy and integration with biomedical workflows. Commercial traction is nascent with no current revenues, and execution risks remain amid a competitive market. Financially, KALA faces capital constraints but retains runway to advance platform validation using proprietary clinical datasets.